<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576131</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1029-01</org_study_id>
    <nct_id>NCT03576131</nct_id>
  </id_info>
  <brief_title>GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors</brief_title>
  <official_title>First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate the safety of GEN1029 (HexaBody®-DR5/DR5) in a mixed&#xD;
      population of patients with specified solid tumors&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is an open-label, multi-center safety trial of GEN1029 (HexaBody®-DR5/DR5). The&#xD;
      trial consists of two parts a dose escalation part (phase 1, first-in-human (FIH) and an&#xD;
      expansion part (phase 2a). The expansion part of the trial will be initiated once the&#xD;
      Recommended Phase 2 Dose (RP2D) has been determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>DLTs will be identified from the two first treatment cycles (28 days, a cycle is 14 days)</time_frame>
    <description>To determine recommended phase 2a dose of GEN1029</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>Throughout and at the end of trial (up to 24 months after first treatment cycle (a treatment cycle is 14 days))</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Urothelial Cancer</condition>
  <arm_group>
    <arm_group_label>GEN1029 (HexaBody®-DR5/DR5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label, single arm trial where GEN1029 will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN1029 (HexaBody®-DR5/DR5)</intervention_name>
    <description>GEN1029 will be administered intravenously once every 14 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.</description>
    <arm_group_label>GEN1029 (HexaBody®-DR5/DR5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (main):&#xD;
&#xD;
          -  Patients with advanced and/or metastatic cancer who have no available standard therapy&#xD;
             or who are not candidates for available standard therapy, and for whom, in the opinion&#xD;
             of the investigator, experimental therapy with GEN1029 may be beneficial.&#xD;
&#xD;
          -  Patient must be ≥ 18 years of age&#xD;
&#xD;
          -  Patients must have measurable disease according to Response Evaluation Criteria In&#xD;
             Solid Tumors (RECIST) version 1.1&#xD;
&#xD;
          -  Have an acceptable hematological status&#xD;
&#xD;
          -  Have an acceptable renal function&#xD;
&#xD;
          -  Have an acceptable liver function&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group performance status of 0 or 1&#xD;
&#xD;
          -  Body weight ≥ 40kg&#xD;
&#xD;
          -  Patients both females and males, of childbearing or reproductive potential must agree&#xD;
             to use adequate contraception from screening visit until six months after last&#xD;
             infusion of GEN1029&#xD;
&#xD;
        Exclusion Criteria (main):&#xD;
&#xD;
          -  Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for&#xD;
             at least 8 weeks prior to first GEN1029 administration&#xD;
&#xD;
          -  Have clinically significant cardiac disease&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or&#xD;
             diastolic blood pressure ≥100 mmHg, despite optimal medical management&#xD;
&#xD;
          -  Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new&#xD;
             (younger than 6 months) or progressive brain metastases or stroke&#xD;
&#xD;
          -  History of organ allograft (except for corneal transplant) or autologous or allogeneic&#xD;
             bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of&#xD;
             Investigational Medicinal Product (IMP)&#xD;
&#xD;
          -  Have received a cumulative dose of corticosteroid ≥ 150 mg prednisone (or equivalent&#xD;
             doses of corticosteroids) within two weeks before the first GEN1029 administration&#xD;
&#xD;
          -  History of ≥ grade 3 allergic reactions to monoclonal antibody therapy as well as&#xD;
             known or suspected allergy or intolerance to any agent given in the course of this&#xD;
             trial&#xD;
&#xD;
          -  Radiotherapy within 14 days prior to first GEN1029 administration&#xD;
&#xD;
          -  Any prior therapy with a compound targeting DR4 or DR5&#xD;
&#xD;
          -  History of chronic liver disease or evidence of hepatic cirrhosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Plummer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Newcastle Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genmab Trial Information</last_name>
    <phone>+45 70202728</phone>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT M.D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univeritario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid CIOCC</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Mardsen NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

